• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific’s drug-coated balloon succeeds in femoropopliteal segment at one year

May 15, 2018 By Sarah Faulkner

Boston ScientificData from Boston Scientific‘s (NYSE:BSX) Ranger SFA trial showed that treatment with its drug-coated balloon succeeded in the femoropopliteal segment after one year and resulted in greater rates of patency, with fewer interventions, compared to standard balloon angioplasty.

The results, which were published this month in JACC: Cardiovascular Interventions, demonstrated that both groups of patients – those treated with Boston Scientific’s Ranger DCB and those treated with standard balloon angioplasty – experienced similar quality-of-life improvements over the course of 12 months.

The 105-patient trial enrolled people with symptomatic lower limb ischemia, a lesion that measured between 20mm and 150mm in length and stenotic lesions in the nonstented superficial femoral artery or proximal popliteal segment, according to a report from Healio.

After one year, patients in the DCB group had a 86% primary patency rate compared to a 56.5% rate in the balloon angioplasty group. Freedom from target lesion revascularization was 91.2% in the DCB group and 69.9% in the balloon angioplasty group.

The researchers also noted that there were no device-related deaths or target limb amputations over the course of the trial.

“The study adds to the available information on peripheral treatment with drug-coated balloons, providing clinical evidence unique to the Ranger drug-coated balloon,” Dr. Sabine Steiner, of the University of Leipzig in Germany, wrote.

In an editorial, Dr. Konstantinos Katsanos of the Patras University Hospital School of Medicine called on researchers to compare paclitaxel-coated balloons directly in head-to-head trials.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS